Literature DB >> 31515402

Impaired right ventricular lusitropy is associated with ventilatory inefficiency in pulmonary arterial hypertension.

Khodr Tello1, Antonia Dalmer2, Rebecca Vanderpool3, Hossein A Ghofrani2,4,5, Robert Naeije6, Fritz Roller7, Werner Seeger2, Daniel Dumitrescu8, Natascha Sommer2, Anne Brunst2, Henning Gall2, Manuel J Richter2.   

Abstract

Cardiopulmonary exercise testing (CPET) is an important tool for assessing functional capacity and prognosis in pulmonary arterial hypertension (PAH). However, the associations of CPET parameters with the adaptation of right ventricular (RV) function to afterload remain incompletely understood.In this study, 37 patients with PAH (idiopathic in 31 cases) underwent single-beat pressure-volume loop measurements of RV end-systolic elastance (Ees), arterial elastance (Ea) and diastolic elastance (Eed). Pulmonary arterial stiffness was assessed by magnetic resonance imaging. The results were correlated to CPET variables. The predictive relevance of RV function parameters for clinically relevant ventilatory inefficiency, defined as minute ventilation/carbon dioxide production (V' E/V' CO2 ) slope >48, was evaluated using logistic regression analysis.The median (interquartile range) of the V' E/V' CO2 slope was 42 (32-52) and the V' E/V' CO2 nadir was 40 (31-44). The mean±sd of peak end-tidal carbon dioxide tension (P ETCO2 ) was 23±8 mmHg. Ea, Eed and parameters reflecting pulmonary arterial stiffness (capacitance and distensibility) correlated with the V' E/V' CO2 slope, V' E/V' CO2 nadir, P ETCO2 and peak oxygen pulse. RV Ees and RV-arterial coupling as assessed by the Ees/Ea ratio showed no correlations with CPET parameters. Ea (univariate OR 7.28, 95% CI 1.20-44.04) and Eed (univariate OR 2.21, 95% CI 0.93-5.26) were significantly associated with ventilatory inefficiency (p<0.10).Our data suggest that impaired RV lusitropy and increased afterload are associated with ventilatory inefficiency in PAH.
Copyright ©ERS 2019.

Entities:  

Year:  2019        PMID: 31515402     DOI: 10.1183/13993003.00342-2019

Source DB:  PubMed          Journal:  Eur Respir J        ISSN: 0903-1936            Impact factor:   16.671


  9 in total

Review 1.  Emerging therapies for right ventricular dysfunction and failure.

Authors:  Anna Klinke; Torben Schubert; Marion Müller; Ekaterina Legchenko; Jason G E Zelt; Tsukasa Shimauchi; L Christian Napp; Alexander M K Rothman; Sébastien Bonnet; Duncan J Stewart; Georg Hansmann; Volker Rudolph
Journal:  Cardiovasc Diagn Ther       Date:  2020-10

2.  Sex Differences in Right Ventricular-Pulmonary Arterial Coupling in Pulmonary Arterial Hypertension.

Authors:  Khodr Tello; Manuel J Richter; Athithan Yogeswaran; Hossein A Ghofrani; Robert Naeije; Rebecca Vanderpool; Henning Gall; Ryan J Tedford; Werner Seeger; Tim Lahm
Journal:  Am J Respir Crit Care Med       Date:  2020-10-01       Impact factor: 21.405

3.  The added value of right ventricular function normalized for afterload to improve risk stratification of patients with pulmonary arterial hypertension.

Authors:  Marco Vicenzi; Sergio Caravita; Irene Rota; Rosa Casella; Gael Deboeck; Lorenzo Beretta; Andrea Lombi; Jean-Luc Vachiery
Journal:  PLoS One       Date:  2022-05-19       Impact factor: 3.752

4.  Kussmaul's Sign in Pulmonary Hypertension Corresponds With Severe Pulmonary Vascular Pathology Rather Than Right Ventricular Diastolic Dysfunction.

Authors:  Fatimah A Alkhunaizi; Michael R Harowicz; Catherine G Ireland; Brian A Houston; Rachel L Damico; Todd M Kolb; Stephen C Mathai; Stefan L Zimmerman; Paul M Hassoun; Ryan J Tedford; Steven Hsu
Journal:  Circ Heart Fail       Date:  2020-12-28       Impact factor: 8.790

Review 5.  The physiological basis of pulmonary arterial hypertension.

Authors:  Robert Naeije; Manuel J Richter; Lewis J Rubin
Journal:  Eur Respir J       Date:  2022-06-16       Impact factor: 33.795

6.  The predictive value of minute ventilation versus carbon dioxide production in pulmonary hypertension associated with left heart disease.

Authors:  Xiujun Zhong; Jie Tang; Rong Jiang; Ping Yuan; Qinhua Zhao; Sugang Gong; Jinming Liu; Lan Wang
Journal:  Ann Transl Med       Date:  2021-02

Review 7.  Clinical significance of pulmonary hypertension in interstitial lung disease: A consensus statement from the Pulmonary Vascular Research Institute's innovative drug development initiative-Group 3 pulmonary hypertension.

Authors:  Sylvia M Nikkho; Manuel J Richter; Eric Shen; Steven H Abman; Katerina Antoniou; Jonathan Chung; Peter Fernandes; Paul Hassoun; Howard M Lazarus; Horst Olschewski; Lucilla Piccari; Mitchell Psotka; Rajan Saggar; Oksana A Shlobin; Norman Stockbridge; Patrizio Vitulo; Carmine Dario Vizza; Stephen J Wort; Steven D Nathan
Journal:  Pulm Circ       Date:  2022-07-01       Impact factor: 2.886

8.  Long-term comprehensive cardiopulmonary phenotyping of COVID-19.

Authors:  Lucas M Kimmig; Zvonimir A Rako; Susanne Herold; Khodr Tello; Ulrich Matt; Stefanie Ziegler; Manuel J Richter; Ashkan Tolou G S; Fritz Roller; Friedrich Grimminger; István Vadász; Werner Seeger
Journal:  Respir Res       Date:  2022-09-21

9.  The tailor-made treatment in a particular case of pulmonary hypertension in thalassaemia intermedia: a case report.

Authors:  Federico B M Blasi; Irene Rota; Giovanna Graziadei; Marco Vicenzi
Journal:  Eur Heart J Case Rep       Date:  2021-06-16
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.